EC approved toripalimab (LOQTORZI®) for the treatment of certain patients with mNPC and ESCC October 2, 2024
Strategic Repositioning of VB10.16 to Focus on Locally Advanced Cervical Cancer and Recurrent Metastatic Head and Neck Cancer August 27, 2024
FDA granted Fast Track Designation to APG-157 for the neoadjuvant treatment of Head and Neck Cancer (HNC) August 27, 2024
BRG01 Receives FDA Approval for Ph 2 Trial for the treatment of relapsed/metastatic EBV-positive NPC August 22, 2024
FAILED TRIAL: FOCUS Ph II Trial of UV1 + Pembrolizumab didn’t improve PFS & OS in Patients with Metastatic or Recurrent Head and Neck Cancer August 13, 2024
FDA Fast Track Designation Granted to Ozuriftamab Vedotin (CAB-ROR2-ADC) for Patients with Recurrent or Metastatic SCCHN August 7, 2024
Ph 2 Plans Announced for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review August 7, 2024
Alignment with FDA on Ph 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer August 7, 2024
BRG01 Enters Ph 2 Clinical Trial For Solid Tumors On Recurrent/Metastatic Nasopharyngeal Carcinoma July 23, 2024
Ph 3 TrilynX study of xevinapant + CRT in patients with unresected LA SCCHN to be discontinued July 1, 2024
Positive Topline Results from TACTI-003 Ph 2b Trial in 1L Head and Neck Cancer announced July 1, 2024
Updated Interim Ph 1/1b Data of Ficerafusp Alfa (BCA101) in 1L HPV-negative Recurrent/Metastatic HNSCC reported July 1, 2024
Tisotumab Vedotin Ph 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic HNSCC June 11, 2024
Adaptimmune and Galapagos Collaborate on uza-cel in Head & Neck Cancer and Potential Future Solid Tumor Indications June 4, 2024
VERSATILE-002 Ph 2 Trial Meets Primary Study Endpoints in 1l Recurrent/Metastatic HPV16-Positive Head and Neck Cancer May 15, 2024
Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in interim assessment of Ph 2 GALAXIES Lung-201 May 15, 2024
Ph 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept + Keytruda in Patients with Untreated HPV-Mediated Oropharyngeal Cancer initiated May 7, 2024
Ph 2/3 pivotal trial design and protocol for HB-200 + Keytruda in 1L HPV16+ recurrent or metastatic oropharyngeal squamous cell carcinoma (OPSCC) aligned with FDA feedback May 1, 2024
